Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE yes for NSCLC diagnostic tests could impact Iressa and Tarceva

This article was originally published in Scrip

Executive Summary

New guidance from NICE, the health technology appraisal institute for England and Wales, recommending EGFR-tyrosine kinase mutation tests for routine use on the National Health Service could improve the treatment of non-small cell lung cancer treatment. It could also impact use of Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib), the two EGFR-TK inhibitors recommended by NICE to treat NSCLC.

You may also be interested in...



Constitutional Complaints In Germany Cast Doubt Over Fate Of UPC

The UK’s withdrawal from the EU could upset the Unitary Patent Court project.

Will COVID-19 Drive The Decline Of International Reference Pricing?

International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.

EU Orphan And Pediatric Proposals Insufficient, Says Industry

Innovators warn against slashing incentives and argue a lack of a common definition of unmet need is a stumbling block to proposals.

Topics

Related Companies

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel